Biotechnology Companies Prepared for a Big 2018

LAS VEGAS, January 25, 2018 /PRNewswire/ --

FN Media Group Presents Microcapspeculators.com News Commentary 

It is increasingly difficult to track biotechnology companies and advancements in medicine as new technologies are developed at a never-before-seen rate. As we begin 2018, it is vital that we attempt to identify trends in an ever-changing industry. Included in today's commentary: Propanc Biopharma, Inc.(OTC: PPCB, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), ImmunoGen, Inc. (NASDAQ: IMGN), PTC Therapeutics, Inc. (NASDAQ: PTCT), and Nevro Corp. (NYSE: NVRO).

One trend within the biotech drug industry that stands out is the change in the customer base for medicine. Historically, doctors were the only customers of Big Pharma companies. That has changed over time from doctors to insurance companies. Now, in 2018, a bigger focus will be on the individual consumer.

There are a few drivers of this trend:

• Drugs are now developed to treat very specific and rare diseases, making the consumer experience feel personalized. Consumers are reaching their diseases and having more of a say in the decision-making around their individualized treatment.
• Media coverage often focuses on miracle stories for dying patients that capture the attention of the nation in ways that hurricanes do not. Miracle stories capture the imagination of the viewer, growing people's interest in what the sector is doing- or capable of.
• Individual treatment has created an opportunity for greater understanding of human biology and the human genome.

As this sector continues to create individualized treatments, the customer base will grow with consumers outnumbering doctors and insurance companies.  

In other biotech news: Propanc Biopharma, Inc.(OTCQB: PPCB), Sarepta Therapeutics, Inc. (NASDAQ: SRPT), ImmunoGen, Inc. (NASDAQ: IMGN), PTC Therapeutics, Inc. (NASDAQ: PTCT), and Nevro Corp. (NYSE: NVRO).

Propanc Biopharma, Inc. (OTCQB: PPCB) 

Market Cap: $3.383M, current share price: $0.175 

PPCB is a clinical stage biopharmaceutical company with a focus on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. This is an exciting time for PPCB as they are headed toward a First-In-Human study with their lead candidate, PRP. As they head toward this next phase of clinical testing, media and public relations are increasingly important. PPCB announced last week that Alan Morell, CEO of Creative Management Partners LLC, will be advising PPCB on a consulting basis. Mr. Morell comes with significant experience in the Microcap sector and across both the pharma and biotech industries. This new hire is projected to increase the growth potential of PPCB as it moves forward in this new and critical phase of company progress.